Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin Alfa Phase 1b in SLE
NCT03451422Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2018
- Primary completion
- Oct 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Efavaleukin Alfa with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events. Started Apr 2018; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03451422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451422.